CD&R Launches Rs 2,983 Crore Open Offer for 26% Stake in Sanofi Consumer Healthcare India

An international investment company, CD&R, has announced plans to acquire a 26% stake in Sanofi Consumer Healthcare India Ltd. This acquisition is valued at up to Rs 2,983 crore. The move comes after Sanofi and Clayton, Dubilier & Rice (CD&R) entered exclusive negotiations. CD&R aims to gain a controlling interest in Opella, which owns 60.4% of Sanofi Consumer Healthcare India.

Representative image

The offer price is set at Rs 4,982.05 per share, totalling up to Rs 2,983.23 crore. This information was disclosed in an offer letter by Citigroup Global Markets India, the transaction manager, and shared on the BSE by Sanofi Consumer Healthcare India. The open offer was initiated following the exclusive negotiations between Sanofi and CD&R for a potential sale and purchase of a 50% controlling stake in Opella.

Opella's Global Presence

Opella, based in France, employs over 11,000 people worldwide. It operates across 100 countries with 13 manufacturing sites and four centres dedicated to science and innovation development. The valuation of Opella is grounded on an enterprise value of 16 billion euros.

Upon finalising the transaction, CD&R will indirectly gain control over 60.40% of the voting rights in Sanofi Consumer Healthcare India. This will allow CD&R to exert significant influence over the company's operations and strategic direction.

The acquisition marks a significant step for CD&R in expanding its footprint within the healthcare sector. By securing a substantial stake in Sanofi Consumer Healthcare India, CD&R positions itself strategically within the Indian market.

The transaction reflects a broader trend of consolidation within the healthcare industry as companies seek to strengthen their market positions through strategic acquisitions and partnerships.